SafetyTector™ S Cat. No. #400 902 ONLY for OEM

SafetyTector™ SafetyTector™ S is a SARS-CoV-2 inactivating extraction and dilution buffer for saliva specimens and nasopharyngeal swabs. Swabs can be extracted directly with SafetyTector™ S. Samples must be diluted in SafetyTector™ S at least 1:4. At this dilution, SafetyTector™ S is able to inactivate SARS-CoV-2 within 1 minute. Therefore the samples are no longer infectious.
£0.00

Choose your options

SafetyTector™

SafetyTector™ S is a SARS-CoV-2 inactivating extraction and dilution buffer for saliva specimens and nasopharyngeal swabs. Swabs can be extracted directly with SafetyTector™ S.


SafetyTector™ S eliminates the high risk of infection during and after testing coming from the specimen or other test materials. Virus inactivation was confirmed and tested with infectious viruses in a Biosafety Level 3 laboratory.

SafetyTector™ S completely eliminates infectivity of SARS-CoV-2

Samples diluted in SafetyTector™ S can directly be used in lateral flow assays and also in other immunoassays such as ELISA, protein arrays oder bead-based assays.

In tests with commercially available SARS-CoV-2 antigen rapid tests, SafetyTector™ S shows comparable or better performance than supplied extraction and dilution buffers. In some cases, further improvement in the detection limit was observed.

The suitability of SafetyTector™ S for the respective assay has to be tested by the manufacturer or distributor.

Safe Design of in vitro diagnostic medical devices (IVD products) is an obligatory pre-requisite for placing them on the international markets in the EU. This is defined in EU legislation (Directive 98/79/EG, Annex I, chapter B, clause 2.1 and Regulation (EU) 2017/746, Annex I, Chapter I, clause 4). Besides that, the ISO 14971 „application of risk management to medical devices“ (ISO 14971:2012, Annex A, chapter A.2.6 risk control) - decisive for the correct implementation of the ISO 13485 - mandates a risk control procedure and thus gives another regulatory binding basis for ensuring that IVDs are safe and secure for the user in all international markets. Safe Design includes that the risk of infection for the user is eliminated or reduced to the lowest possible level – this is especially important for IVDs for highly infectious viruses such as SARS-CoV-2. The current pandemic situation with the highly infectious variants of SARS-CoV-2 forces immediate action even for IVD products already on the market.

Virus-inactivating extraction buffers are an easy-to-use and effective tool to produce IVDs in conformity with these mandatory regulations.
During the past there were no virus-inactivating extraction buffers, proven to be able to inactivate SARS-CoV-2 by experiments under real conditions with infective viruses, available on the market.

SafetyTector™ S thus sets a current state of the art in terms of safe design for user safety during antibody- and antigen-tests – especially in rapid lateral flow testing. Testing virus inactivation with substitute test materials such as virus-like particles (VLPs) cannot safely allow the same conclusions in terms of user safety.
Together with SafetyTector™ S, manufacturers of IVD directly get the necessary evidence for virus inactivation in form of a “Letter of Acknowledgement” from the testing Biosafety Level 3 laboratory.


Download Product Resources

 SARS-CoV-2 antigen tests: safety for less than 5 cents per test 

Product Descriptions & Guides
​​​​​​​

Product Inserts and Data Sheets

Brand CANDOR Bioscience
Code 400 902

Product Flyers and Application Guides

 BIOAXXESS CANDOR Blocker Selection Guide NEW
BIOAXXESS CANDOR Product Application Guide
 CANDOR Products Brochure
 Assay Defender® Flyer NEW
 Assay Defender® Use NEW
 Assay Defender® LowCross-Buffer® Comparison Matrix NEW
 SafetyTector™ S NEW
 


Product Inserts and Data Sheets

Assay Optimizers

 Assay Defender® NEW
 LowCross-Buffer® 
 LowCross-Buffer® ​​​​​Mild
 LowCross-Buffer® Strong
 LowCross-Buffer® Animal-free/Protein-free
 LowCross-Buffer® ​​​​​Mild Animal-free/Protein-free
 LowCross-Buffer® ​​​​​Strong Animal-free/Protein-free
 Low-Cross-HRP® 
 LowCross® HRP-Stab
 LowCross® HRP-Stab Animal-free/Protein-free
 LowCross® HRP-Stab Mild Animal-free/Protein-free
 LowCross® HRP-Stab Strong Animal-free/Protein-free
 Sample Buffer
 Sample Buffer Animal-free/Protein-free
 Sample Buffer IHC


Covid-19 Inactivation and Dilution Buffer

 SafetyTector™ S NEW
 

Blockers

 The Blocking Solution 
 BSA-Block 
 PlateBlock™ NEW
 SmartBlock™


Stabilizers

 Antibody Stabilizer TRIS
 Antibody Stabilizer TRIS Animal-free/Protein-free
 Antibody Stabilizer PBS
 Antibody Stabilizer PBS Animal-free/Protein-free
 AP-Protector®
 Liquid Plate Sealer®
 Liquid Plate Sealer® Animal-free
 HRP-Protector™
 HRP-Protector™ Animal-free/Protein-free
 HRP-Protector™ TRIS
 HRP-Protector™ TRIS Animal-free/Protein-free
 HRP-Protector™ PBS
 HRP-Protector™ PBS Animal-free/Protein-free


Standard Buffers (ready-made)

 Coating Buffer pH 7.4 
 Coating Buffer pH 9.6 
 Stripping Buffer 
 Washing Buffer ReadyTector®
 Washing Buffer TRIS
 Washing Buffer TRIS IHC
 Washing Buffer PBS 
 Washing Buffer PBS IHC


All-in-One Western Blotting Solution

 ReadyTector®
 ReadyTector® Anti-Mouse
 ReadyTector® Anti-Rabbit


Tool boxes

 Blocking Sampler Package with BSA Block
 CANDOR Starter Package
 CANDOR Starter Package IHC
 


Publications

 CoViD-19-antibody-test-challenge
 Interference and HAMA problems
 IVD Technology Article
 Long-term stabilization of assay components
 Optimisation of assays: Interference in immunoassays recognize and avoid 
 SARS-CoV-2 antigen tests: safety for less than 5 cents per test 
 Specificity, positive predictive value and validation statistics in the context of CoViD-19
 The Appropriate Blocker — A Short Overview
 The right strategy saves much costs